Description: Napabucasin, also known as BBI-608, is an orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, BBI608 appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.
Synonym: BBI608; BBI 608; BB-I608; Napabucasin
IUPAC/Chemical Name: 2-Acetylnaphtho[2,3-b]furan-4,9-dione
Chemical Formula: C14H8O4
Exact Mass: 240.0423
Molecular Weight: 240.214
Elemental Analysis: C, 70.00; H, 3.36; O, 26.64
1: Zhang Y, Jin Z, Zhou H, Ou X, Xu Y, Li H, Liu C, Li B. Suppression of prostate
cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med.
2016 Feb 21. doi: 10.1002/cam4.675. [Epub ahead of print] PubMed PMID: 26899963.
2: Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, Leggett D, Li W,
Pardee AB, Li CJ. Suppression of cancer relapse and metastasis by inhibiting
cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi:
10.1073/pnas.1424171112. Epub 2015 Jan 20. PubMed PMID: 25605917; PubMed Central